Immunocore Holdings (IMCR) Revenue (2023 - 2026)

Immunocore Holdings (IMCR) has 4 years of Revenue data on file, last reported at $106.7 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 13.63% year-over-year to $106.7 million; the trailing twelve-month figure through Mar 2026 stood at $412.8 million (up 23.75% YoY), and the FY2025 full-year result was $400.0 million, up 28.95% from the prior year.
• Revenue grew to $106.7 million in Q1 2026, from $104.5 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $106.7 million in Q1 2026 to a low of $54.7 million in Q1 2023.
• A 4-year average of $82.0 million and a median of $80.2 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue soared 33.16% in 2025 and rose 13.63% in 2026, its largest moves.
• Tracing IMCR's Revenue over 4 years: stood at $70.2 million in 2023, then increased by 19.8% to $84.1 million in 2024, then gained by 24.3% to $104.5 million in 2025, then rose by 2.1% to $106.7 million in 2026.
• Business Quant data shows IMCR's Revenue at $106.7 million in Q1 2026, $104.5 million in Q4 2025, and $103.7 million in Q3 2025.